Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992
- PMID: 9635529
Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992
Abstract
Background: Little is known about the cause of inflammatory breast carcinoma (IBC), the most aggressive form of breast cancer. To the authors' knowledge, no studies have investigated whether IBC risk factors are different from those for breast carcinoma overall, and there has been only one report of IBC incidence and survival patterns.
Methods: The authors used data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute for the period 1975-1992 to calculate age-adjusted incidence and survival rates for 913 white and 121 African American women with IBC involving dermal invasion of lymphatic ducts and 166,375 white and 13,674 African American women with other types of breast carcinoma (non-IBC).
Results: Between 1975-1977 and 1990-1992, IBC incidence doubled, increasing among whites from 0.3 to 0.7 cases per 100,000 person-years and among African Americans from 0.6 to 1.1 cases. However, rates for African Americans varied due to the small numbers of IBC cases. The twofold increase in IBC incidence was higher than that observed for non-IBC during the same period (27% for African Americans and 25% for whites). IBC patients were significantly younger at diagnosis than non-IBC patients; and among both IBC and non-IBC patients, African Americans were younger than whites. Overall survival was significantly worse for IBC patients than for non-IBC patients and for African Americans than for whites. Among whites, 3-year survival improved more for IBC patients than for non-IBC patients between 1975-1979 and 1988-1992, increasing from 32% to 42% for IBC patients (P=0.0001) and from 80% to 85% for non-IBC patients (P=0.0001).
Conclusions: The disparities observed in incidence trends and age at diagnosis, particularly according to race, highlight the need for further investigation of the differences between IBC and non-IBC incidence.
Similar articles
-
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.J Natl Cancer Inst. 2005 Jul 6;97(13):966-75. doi: 10.1093/jnci/dji172. J Natl Cancer Inst. 2005. PMID: 15998949 Free PMC article.
-
Persistence in breast cancer disparities between African Americans and whites in Wisconsin.WMJ. 2011 Feb;110(1):21-5. WMJ. 2011. PMID: 21473509 Free PMC article.
-
Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.Breast Cancer Res Treat. 2023 Sep;201(2):275-287. doi: 10.1007/s10549-023-07018-7. Epub 2023 Jul 13. Breast Cancer Res Treat. 2023. PMID: 37442877
-
Differences in cancer incidence, mortality, and survival between African Americans and whites.Environ Health Perspect. 1995 Nov;103 Suppl 8(Suppl 8):275-81. doi: 10.1289/ehp.95103s8275. Environ Health Perspect. 1995. PMID: 8741798 Free PMC article. Review.
-
The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.J Womens Health (Larchmt). 2009 Jun;18(6):883-93. doi: 10.1089/jwh.2008.1127. J Womens Health (Larchmt). 2009. PMID: 19514831 Review.
Cited by
-
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening.Oncotarget. 2015 Aug 28;6(25):21255-67. doi: 10.18632/oncotarget.4013. Oncotarget. 2015. PMID: 26101913 Free PMC article.
-
Lymph node status in inflammatory breast cancer.Breast Cancer Res Treat. 2015 May;151(1):113-20. doi: 10.1007/s10549-015-3367-6. Epub 2015 Apr 7. Breast Cancer Res Treat. 2015. PMID: 25846421 Free PMC article.
-
Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: a SEER population-based study.PeerJ. 2019 Sep 16;7:e7659. doi: 10.7717/peerj.7659. eCollection 2019. PeerJ. 2019. PMID: 31576238 Free PMC article.
-
Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors.Int J Mol Sci. 2021 Aug 10;22(16):8581. doi: 10.3390/ijms22168581. Int J Mol Sci. 2021. PMID: 34445288 Free PMC article.
-
Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.Cancer Epidemiol. 2016 Feb;40:7-14. doi: 10.1016/j.canep.2015.11.003. Epub 2015 Nov 21. Cancer Epidemiol. 2016. PMID: 26605428 Free PMC article.